RxDoctor Payments Data

Ivory Kinslow, MD

Ophthalmology · El Dorado, ARNPI 1972575702

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 45 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Alcon at 34.6% of the total. That places this record below the midpoint for ophthalmology clinicians in AR, where the typical reported total is $697.

$827in general payments, 2019–2025

Across 45 payments — averaging $18.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$286
  • AbbVie$283
  • Glaukos Corporation$147
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$39
  • Dompe US, Inc.$23
  • Rxsight Inc$18
  • plus $30 from 2 others

What the payments were for

  • Food & beverage$827100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$827 in reported general payments places this provider in the 50th percentile of 125 ophthalmology providers in Arkansas.

See all ophthalmology providers in Arkansas

Medicare billing

Part B allowed, 2024
$450,379
Medicare patients
662
Services billed
2,767

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost28$12,100
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha660$7,480
RestasisCyclosporine12$6,565
CombiganBrimonidine Tartrate/Timolol17$5,497
Travoprost22$2,995
Latanoprost281$2,839
Prednisolone Acetate56$2,585
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol11$1,969
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat104$1,750
ErythromycinErythromycin Base81$877
Timolol Maleate80$742
Brimonidine Tartrate105$630
Ketorolac Tromethamine14$418
Doxycycline Hyclate16$291
Dorzolamide Hcl16$253

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan$283$24,16157 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 125 ophthalmology providers in Arkansas.

Other ophthalmology in El Dorado

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →